Stocks Overview

LAST PRICE
37.2900
TODAY'S CHANGE (%)
Trending Up0.2000 (0.5392%)

Bid / Lots
37.2800/ 1
Ask / Lots
37.3500/ 3
Open / Previous Close
37.4000 / 37.0900
Day Range
Low 36.8400
High 37.9485
52 Week Range
Low 27.9850
High 50.9900
Volume
187,942
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 37.09
Time	Volume	XENE
09:32 ET	1444	37.4
09:34 ET	400	37.51
09:36 ET	100	36.84
09:38 ET	100	36.86
09:39 ET	100	36.87
09:43 ET	100	37.15
09:45 ET	300	37.33
09:48 ET	100	37.38
09:50 ET	543	37.43
09:52 ET	400	37.4
09:54 ET	300	37.21
09:56 ET	100	37.14
09:57 ET	600	37.03
09:59 ET	400	37.19
10:03 ET	100	37.16
10:06 ET	200	37.11
10:08 ET	746	37.27
10:10 ET	300	37.3
10:12 ET	100	37.21
10:14 ET	100	37.19
10:15 ET	100	37.31
10:17 ET	100	37.19
10:19 ET	300	37.355
10:21 ET	100	37.29
10:24 ET	200	37.28
10:26 ET	100	37.24
10:28 ET	100	37.17
10:30 ET	300	37.355
10:32 ET	298	37.23
10:33 ET	30600	37.38
10:35 ET	400	37.18
10:37 ET	100	37.38
10:39 ET	200	37.38
10:42 ET	200	37.325
10:44 ET	200	37.325
10:46 ET	1380	37.59
10:48 ET	100	37.45
10:50 ET	100	37.515
10:51 ET	400	37.58
10:53 ET	200	37.53
10:55 ET	200	37.555
10:57 ET	600	37.64
11:00 ET	400	37.64
11:02 ET	300	37.75
11:04 ET	7629	37.03
11:06 ET	100	37
11:08 ET	100	37
11:09 ET	860	37.23
11:11 ET	300	37.24
11:13 ET	400	37.28
11:15 ET	100	37.19
11:18 ET	384	37.33
11:20 ET	300	37.26
11:22 ET	400	37.265
11:24 ET	100	37.33
11:26 ET	800	37.44
11:27 ET	300	37.47
11:29 ET	300	37.495
11:31 ET	300	37.46
11:33 ET	800	37.22
11:36 ET	3826	37.24
11:38 ET	100	37.14
11:40 ET	200	37.185
11:42 ET	400	37.175
11:44 ET	100	37.11
11:45 ET	200	37.06
11:49 ET	200	37.18
11:51 ET	700	37.12
11:54 ET	200	37.165
11:56 ET	100	37.11
11:58 ET	200	37.21
12:00 ET	400	37.165
12:02 ET	600	37.2
12:03 ET	300	37.28
12:05 ET	200	37.25
12:07 ET	710	37.15
12:09 ET	100	37.09
12:14 ET	100	37.06
12:16 ET	800	37.095
12:18 ET	1007	37
12:20 ET	13668	37
12:21 ET	300	37.07
12:23 ET	100	37.04
12:25 ET	200	37.05
12:27 ET	300	37.085
12:30 ET	896	37.14
12:32 ET	100	37.11
12:34 ET	2100	37.135
12:36 ET	200	37.13
12:38 ET	100	37.06
12:39 ET	400	37.14
12:41 ET	100	37.1
12:43 ET	300	37.19
12:45 ET	300	37.25
12:48 ET	700	37.18
12:50 ET	300	37.1
12:52 ET	300	37
12:54 ET	100	37.075
12:56 ET	300	37.08
12:57 ET	700	37.29
12:59 ET	100	37.28
01:01 ET	604	37.335
01:03 ET	200	37.31
01:06 ET	300	37.4
01:08 ET	300	37.385
01:10 ET	400	37.4
01:12 ET	300	37.41
01:14 ET	971	37.35
01:15 ET	500	37.3
01:17 ET	100	37.32
01:19 ET	200	37.39
01:21 ET	100	37.31
01:24 ET	500	37.345
01:26 ET	200	37.27
01:30 ET	200	37.27
01:33 ET	200	37.32
01:35 ET	400	37.39
01:37 ET	1939	37.38
01:39 ET	200	37.32
01:42 ET	200	37.365
01:44 ET	100	37.365
01:46 ET	400	37.315
01:48 ET	200	37.315
01:50 ET	200	37.315
01:51 ET	300	37.26
01:53 ET	808	37.29
01:55 ET	200	37.25
01:57 ET	100	37.22
02:00 ET	400	37.2
02:02 ET	200	37.18
02:04 ET	200	37.18
02:06 ET	200	37.2375
02:08 ET	300	37.24
02:11 ET	580	37.215
02:13 ET	600	37.28
02:15 ET	100	37.28
02:18 ET	100	37.37
02:20 ET	758	37.29
02:22 ET	400	37.31
02:24 ET	100	37.29
02:26 ET	200	37.32
02:27 ET	1095	37.29
02:29 ET	1114	37.2
02:31 ET	400	37.15
02:33 ET	200	37.2
02:36 ET	200	37.15
02:38 ET	895	37.15
02:40 ET	400	37.18
02:42 ET	204	37.22
02:44 ET	400	37.18
02:45 ET	266	37.195
02:47 ET	700	37.26
02:49 ET	200	37.25
02:51 ET	569	37.33
02:54 ET	200	37.245
02:56 ET	200	37.29
02:58 ET	100	37.29
03:00 ET	200	37.295
03:02 ET	600	37.3
03:03 ET	700	37.36
03:05 ET	1117	37.4
03:07 ET	1431	37.38
03:09 ET	1600	37.215
03:12 ET	669	37.195
03:14 ET	300	37.2
03:16 ET	1338	37.18
03:18 ET	482	37.21
03:20 ET	500	37.17
03:21 ET	500	37.27
03:23 ET	986	37.33
03:27 ET	448	37.3
03:30 ET	407	37.32
03:32 ET	100	37.28
03:34 ET	500	37.19
03:36 ET	200	37.19
03:38 ET	200	37.15
03:39 ET	884	37.195
03:41 ET	528	37.25
03:43 ET	1256	37.29
03:45 ET	300	37.28
03:48 ET	400	37.29
03:50 ET	100	37.29

Data delayed at least 15 minutes.

Jun 18, 2024
- DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
  8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 5, 2024
- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
  4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting, from 8:30AM ET on Tuesday May 28, 2024 by Dow Jones
  8:30AM ET on Tuesday May 28, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesXENE Xenon Pharmaceuticals Inc	2.8B	-13.7x	---
United StatesGPCR Structure Therapeutics Inc	2.7B	-19.4x	---
United StatesSWTX SpringWorks Therapeutics Inc	2.7B	-7.0x	---
United StatesBHVN Biohaven Ltd	3.0B	-5.0x	---
United StatesGERN Geron Corp	2.6B	-13.2x	---
United StatesIDYA IDEAYA Biosciences Inc	2.7B	-18.2x	---
As of 2024-06-21

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters: 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone: 604-484-3300
Fax: 604-484-3450

Executives

Chairman of the Board: Simon Pimstone
President, Chief Executive Officer, Director: Ian Mortimer
Chief Financial Officer: Sherry Aulin
Executive Vice President - Drug Discovery: James Empfield
Executive Vice President - Strategy and Innovation: Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.8B
Revenue (TTM)	$0.00
Shares Outstanding	75.5M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.26
EPS	$-2.71
Book Value	$12.31
P/E Ratio	-13.7x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Xenon Pharmaceuticals Inc
NASDAQ:XENEUnited States

Search Criteria

Charts

Recent News

Jun 18, 2024

DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones

Jun 5, 2024

Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones

May 28, 2024

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting, from 8:30AM ET on Tuesday May 28, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar